{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T00:04:09Z","timestamp":1794528249053,"version":"4.9.1"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck & Co., Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epigenetic regulators represent a novel strategy to modulate the tumor immune microenvironment in pancreatic ductal adenocarcinoma (PDAC). In preclinical models, DNA hypomethylating agents enhance cytotoxic T-cell infiltration, synergize with PD-1 blockade, and improve survival when combined with immune checkpoint blockade. This single-institution, phase II study evaluated the safety, efficacy, and biomarkers of azacitidine plus pembrolizumab in patients with previously treated PDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with locally advanced or metastatic PDAC after one prior regimen received 50\u2009mg\/m2 subcutaneous azacitidine on days 1-5 of a 28-day cycle, starting week 1, and pembrolizumab 200\u2009mg intravenously every 3\u2009weeks starting week 3. Baseline and on-treatment blood and tumor was collected for exploratory biomarker analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-six patients enrolled between October 2017 and September 2021 (median age: 62.5\u2009years); 34 were evaluable for safety; 31 for efficacy. Treatment was generally well-tolerated, with Grade 1-2 fatigue and diarrhea most common AEs. Three patients (9.7%) had a partial response, and the disease control rate was 35.5%. Median progression-free and overall survival was 1.51 and 4.83\u2009months, respectively. Exploratory analysis suggested higher baseline CD8+ T cells and lower tumor Ki-67 was associated with response, whereas low baseline CD8+ T cell and Granzyme B infiltration correlated with higher exponential tumor growth rate. PD-L1 and CD68 expression were not predictive of benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Azacitidine plus pembrolizumab demonstrated limited clinical activity in second line, locally advanced or metastatic PDAC. Biomarker analysis suggests higher baseline CD8+ T-cell infiltration and lower proliferative index may identify patients more likely to benefit. Clinical trial registration number: NCT03264404.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag091","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:55:57Z","timestamp":1773806157000},"source":"Crossref","is-referenced-by-count":4,"title":["Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0181-6007","authenticated-orcid":false,"given":"Rachael A","family":"Safyan","sequence":"first","affiliation":[{"name":"University of Washington School of Medicine , Seattle, WA, 98195,","place":["United States"]},{"name":"Fred Hutchinson Cancer Center , Seattle, WA, 98109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth A","family":"White","sequence":"additional","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center, NYU Langone Health , New York, NY, 10016,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas A","family":"Gonda","sequence":"additional","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center, NYU Langone Health , New York, NY, 10016,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shing M","family":"Lee","sequence":"additional","affiliation":[{"name":"Columbia University Mailman School of Public Health , New York, NY, 10032,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiying","family":"Han","sequence":"additional","affiliation":[{"name":"Columbia University Mailman School of Public Health , New York, NY, 10032,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Kuriakose","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center , New York, NY, 10032,","place":["United States"]},{"name":"James J. Peters Bronx VA Medical Center Department of Medicine, , Bronx, NY, 10468,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi K","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center , Seattle, WA, 98109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sita","family":"Kugel","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center , Seattle, WA, 98109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob K","family":"Jamison","sequence":"additional","affiliation":[{"name":"Cornell University Weill Medical College, , New York, NY, 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulam A","family":"Manji","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center , New York, NY, 10032,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center , Cleveland, OH, 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E","family":"Oberstein","sequence":"additional","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center, NYU Langone Health , New York, NY, 10016,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6708-0330","authenticated-orcid":false,"given":"Susan E","family":"Bates","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center , New York, NY, 10032,","place":["United States"]},{"name":"James J. Peters Bronx VA Medical Center Department of Medicine, , Bronx, NY, 10468,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"2026040814513777000_oyag091-B1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/oncolo\/oyac217","article-title":"Tumor growth rate informs treatment efficacy in metastatic pancreatic adenocarcinoma: application of a growth and regression model to pivotal trial and real-world data","volume":"28","author":"Yeh","year":"2023","journal-title":"Oncologist"},{"key":"2026040814513777000_oyag091-B2","doi-asserted-by":"publisher","first-page":"e2100267","DOI":"10.1200\/PO.21.00267","article-title":"Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers","volume":"6","author":"Garmezy","year":"2022","journal-title":"JCO Precis Oncol."},{"key":"2026040814513777000_oyag091-B3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026040814513777000_oyag091-B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2022.0611","article-title":"Ipilimumab\/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency pathogenic germline variants","volume":"8","author":"Terrero","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026040814513777000_oyag091-B5","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat Commun"},{"key":"2026040814513777000_oyag091-B6","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026040814513777000_oyag091-B7","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1158\/0008-5472.CAN-20-0285","article-title":"A DNA hypomethylating drug alters the tumor microenvironment and improves the effectiveness of immune checkpoint inhibitors in a mouse model of pancreatic cancer","volume":"80","author":"Gonda","year":"2020","journal-title":"Cancer Res"},{"key":"2026040814513777000_oyag091-B8","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1158\/0008-5472.CAN-12-1880","article-title":"Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma","volume":"73","author":"Shakya","year":"2013","journal-title":"Cancer Res"},{"key":"2026040814513777000_oyag091-B9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.immuni.2011.06.015","article-title":"Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells","volume":"35","author":"Youngblood","year":"2011","journal-title":"Immunity"},{"key":"2026040814513777000_oyag091-B10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.immuni.2023.12.006","article-title":"Reversible, tunable epigenetic silencing of TCF1 generates flexibility in the T cell memory decision","volume":"57","author":"Abadie","year":"2024","journal-title":"Immunity"},{"key":"2026040814513777000_oyag091-B11","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1158\/1078-0432.CCR-24-2200","article-title":"HMGA2 expression predicts subtype, survival, and treatment outcome in pancreatic ductal adenocarcinoma","volume":"31","author":"Yamamoto","year":"2025","journal-title":"Clin Cancer Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag091\/67385794\/oyag091.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag091\/67385794\/oyag091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag091\/67385794\/oyag091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T18:51:42Z","timestamp":1775674302000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag091\/8527013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag091","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,9]]},"article-number":"oyag091"}}